Logo image of IBS.LS

IBERSOL SGPS SA (IBS.LS) Stock Fundamental Analysis

ELI:IBS - Euronext Lisbon - PTIBS0AM0008 - Common Stock - Currency: EUR

9.5  +0.2 (+2.15%)

Fundamental Rating

4

Taking everything into account, IBS scores 4 out of 10 in our fundamental rating. IBS was compared to 54 industry peers in the Hotels, Restaurants & Leisure industry. Both the profitability and the financial health of IBS get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, IBS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year IBS was profitable.
In the past year IBS had a positive cash flow from operations.
Of the past 5 years IBS 4 years were profitable.
Each year in the past 5 years IBS had a positive operating cash flow.
IBS.LS Yearly Net Income VS EBIT VS OCF VS FCFIBS.LS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

1.2 Ratios

Looking at the Return On Assets, with a value of 2.32%, IBS is in line with its industry, outperforming 48.15% of the companies in the same industry.
IBS has a Return On Equity (4.95%) which is in line with its industry peers.
IBS's Return On Invested Capital of 3.03% is in line compared to the rest of the industry. IBS outperforms 40.74% of its industry peers.
IBS had an Average Return On Invested Capital over the past 3 years of 4.73%. This is significantly below the industry average of 11.61%.
Industry RankSector Rank
ROA 2.32%
ROE 4.95%
ROIC 3.03%
ROA(3y)10.54%
ROA(5y)5.26%
ROE(3y)19.9%
ROE(5y)6.52%
ROIC(3y)4.73%
ROIC(5y)N/A
IBS.LS Yearly ROA, ROE, ROICIBS.LS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

1.3 Margins

Looking at the Profit Margin, with a value of 3.72%, IBS is in line with its industry, outperforming 51.85% of the companies in the same industry.
In the last couple of years the Profit Margin of IBS has declined.
Looking at the Operating Margin, with a value of 4.91%, IBS is in line with its industry, outperforming 44.44% of the companies in the same industry.
IBS's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 48.89%, IBS perfoms like the industry average, outperforming 53.70% of the companies in the same industry.
In the last couple of years the Gross Margin of IBS has remained more or less at the same level.
Industry RankSector Rank
OM 4.91%
PM (TTM) 3.72%
GM 48.89%
OM growth 3YN/A
OM growth 5Y-6.14%
PM growth 3YN/A
PM growth 5Y-7.85%
GM growth 3Y4.13%
GM growth 5Y-0.15%
IBS.LS Yearly Profit, Operating, Gross MarginsIBS.LS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IBS is destroying value.
IBS has about the same amout of shares outstanding than it did 1 year ago.
IBS has more shares outstanding than it did 5 years ago.
IBS has a worse debt/assets ratio than last year.
IBS.LS Yearly Shares OutstandingIBS.LS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
IBS.LS Yearly Total Debt VS Total AssetsIBS.LS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 1.98 indicates that IBS is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 1.98, IBS perfoms like the industry average, outperforming 57.41% of the companies in the same industry.
The Debt to FCF ratio of IBS is 6.77, which is on the high side as it means it would take IBS, 6.77 years of fcf income to pay off all of its debts.
IBS has a Debt to FCF ratio of 6.77. This is comparable to the rest of the industry: IBS outperforms 53.70% of its industry peers.
IBS has a Debt/Equity ratio of 0.69. This is a neutral value indicating IBS is somewhat dependend on debt financing.
IBS's Debt to Equity ratio of 0.69 is fine compared to the rest of the industry. IBS outperforms 61.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 6.77
Altman-Z 1.98
ROIC/WACC0.46
WACC6.52%
IBS.LS Yearly LT Debt VS Equity VS FCFIBS.LS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

IBS has a Current Ratio of 1.38. This is a normal value and indicates that IBS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.38, IBS is in the better half of the industry, outperforming 74.07% of the companies in the same industry.
A Quick Ratio of 1.28 indicates that IBS should not have too much problems paying its short term obligations.
IBS has a better Quick ratio (1.28) than 74.07% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.28
IBS.LS Yearly Current Assets VS Current LiabilitesIBS.LS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

IBS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.97%.
The earnings per share for IBS have been decreasing by -13.58% on average. This is quite bad
IBS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.51%.
Measured over the past years, IBS shows a decrease in Revenue. The Revenue has been decreasing by -1.46% on average per year.
EPS 1Y (TTM)-88.97%
EPS 3YN/A
EPS 5Y-13.58%
EPS Q2Q%12.5%
Revenue 1Y (TTM)10.51%
Revenue growth 3Y13.12%
Revenue growth 5Y-1.46%
Sales Q2Q%16.68%

3.2 Future

IBS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.95% yearly.
IBS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.37% yearly.
EPS Next Y2.42%
EPS Next 2Y16.4%
EPS Next 3Y17.27%
EPS Next 5Y17.95%
Revenue Next Year9.99%
Revenue Next 2Y8.56%
Revenue Next 3Y8.26%
Revenue Next 5Y6.37%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBS.LS Yearly Revenue VS EstimatesIBS.LS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
IBS.LS Yearly EPS VS EstimatesIBS.LS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 23.75 indicates a rather expensive valuation of IBS.
Compared to the rest of the industry, the Price/Earnings ratio of IBS indicates a somewhat cheap valuation: IBS is cheaper than 66.67% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 28.10. IBS is around the same levels.
IBS is valuated rather expensively with a Price/Forward Earnings ratio of 22.40.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IBS is on the same level as its industry peers.
IBS is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 20.74, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 23.75
Fwd PE 22.4
IBS.LS Price Earnings VS Forward Price EarningsIBS.LS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, IBS is valued a bit cheaper than the industry average as 77.78% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.23
EV/EBITDA N/A
IBS.LS Per share dataIBS.LS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IBS does not grow enough to justify the current Price/Earnings ratio.
IBS's earnings are expected to grow with 17.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)9.82
PEG (5Y)N/A
EPS Next 2Y16.4%
EPS Next 3Y17.27%

More info and screens

6

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.38%, IBS is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.10, IBS pays a better dividend. On top of this IBS pays more dividend than 94.44% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.43, IBS pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.38%

5.2 History

The dividend of IBS is nicely growing with an annual growth rate of 31.58%!
Dividend Growth(5Y)31.58%
Div Incr Years1
Div Non Decr Years1
IBS.LS Yearly Dividends per shareIBS.LS Yearly Dividends per shareYearly Dividends per share 2019 2022 2023 2024 0.2 0.4 0.6

5.3 Sustainability

IBS pays out 122.87% of its income as dividend. This is not a sustainable payout ratio.
The dividend of IBS is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP122.87%
EPS Next 2Y16.4%
EPS Next 3Y17.27%
IBS.LS Yearly Income VS Free CF VS DividendIBS.LS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M
IBS.LS Dividend Payout.IBS.LS Dividend Payout, showing the Payout Ratio.IBS.LS Dividend Payout.PayoutRetained Earnings

More info and screens

IBERSOL SGPS SA

ELI:IBS (5/5/2025, 7:00:00 PM)

9.5

+0.2 (+2.15%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)11-29 2024-11-29/amc
Earnings (Next)05-30 2025-05-30
Inst Owners23.23%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap394.35M
Analysts80
Price Target12.16 (28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.38%
Yearly Dividend0.7
Dividend Growth(5Y)31.58%
DP122.87%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.44%
Min EPS beat(2)-25.74%
Max EPS beat(2)-15.13%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.23%
Min Revenue beat(2)0.18%
Max Revenue beat(2)10.27%
Revenue beat(4)4
Avg Revenue beat(4)6.97%
Min Revenue beat(4)0.18%
Max Revenue beat(4)10.27%
Revenue beat(8)6
Avg Revenue beat(8)5.69%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.56%
PT rev (3m)2.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.31%
EPS NY rev (3m)-2.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.93%
Revenue NY rev (3m)0.93%
Valuation
Industry RankSector Rank
PE 23.75
Fwd PE 22.4
P/S 0.87
P/FCF 9.23
P/OCF 5.12
P/B 1.16
P/tB 1.61
EV/EBITDA N/A
EPS(TTM)0.4
EY4.21%
EPS(NY)0.42
Fwd EY4.47%
FCF(TTM)1.03
FCFY10.83%
OCF(TTM)1.86
OCFY19.53%
SpS10.95
BVpS8.22
TBVpS5.89
PEG (NY)9.82
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.32%
ROE 4.95%
ROCE 3.84%
ROIC 3.03%
ROICexc 4.07%
ROICexgc 5.24%
OM 4.91%
PM (TTM) 3.72%
GM 48.89%
FCFM 9.4%
ROA(3y)10.54%
ROA(5y)5.26%
ROE(3y)19.9%
ROE(5y)6.52%
ROIC(3y)4.73%
ROIC(5y)N/A
ROICexc(3y)6.92%
ROICexc(5y)N/A
ROICexgc(3y)9.56%
ROICexgc(5y)N/A
ROCE(3y)5.99%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-20.96%
ROICexc growth 3YN/A
ROICexc growth 5Y-13.96%
OM growth 3YN/A
OM growth 5Y-6.14%
PM growth 3YN/A
PM growth 5Y-7.85%
GM growth 3Y4.13%
GM growth 5Y-0.15%
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 6.77
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 7.55%
Interest Coverage 250
Cash Conversion N/A
Profit Quality 252.85%
Current Ratio 1.38
Quick Ratio 1.28
Altman-Z 1.98
F-Score6
WACC6.52%
ROIC/WACC0.46
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)12.95%
Cap/Sales(5y)11.86%
Profit Quality(3y)143.97%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.97%
EPS 3YN/A
EPS 5Y-13.58%
EPS Q2Q%12.5%
EPS Next Y2.42%
EPS Next 2Y16.4%
EPS Next 3Y17.27%
EPS Next 5Y17.95%
Revenue 1Y (TTM)10.51%
Revenue growth 3Y13.12%
Revenue growth 5Y-1.46%
Sales Q2Q%16.68%
Revenue Next Year9.99%
Revenue Next 2Y8.56%
Revenue Next 3Y8.26%
Revenue Next 5Y6.37%
EBIT growth 1Y-21.52%
EBIT growth 3YN/A
EBIT growth 5Y-7.51%
EBIT Next Year304.41%
EBIT Next 3Y78.76%
EBIT Next 5Y56.64%
FCF growth 1Y-28.97%
FCF growth 3YN/A
FCF growth 5Y20.7%
OCF growth 1Y-29.99%
OCF growth 3Y45.49%
OCF growth 5Y10.5%